Part,  Chapter, Paragraph

  1    I,     2.  4.  0(1) |        EUROSTAT Newsrelease 19/2009, 13 February 2009. [accessed
  2    I,     2. 10.  4(20)|              Healthcare Confererence 13-15 June 2006, Minneapolis,
  3    I,     3.  1        |           the United Kingdom, and 12-13% in Italy and the Netherlands;
  4    I,     3.  2        |              EU.~ ~ ~In 1960, around 13 per cent of the world’s
  5   II,     4.  1        |            65.3 years to 78.5 years (13.2 years gap) for men and
  6   II,     4.  1        |            10.4 years to 24.1 years (13.7 years gap) for women,
  7   II,     4.  1        |        expectancies at birth is over 13 years for men and over 7
  8   II,     4.  1        |         reach 14.5 years for men and 13.7 years for women, highlighting
  9   II,     4.  1        |             Approach for the EU 2008-13” has as the first of its
 10   II,     4.  2        |            shows the contribution of 13 selected causes of death
 11   II,     4.  2        |    expectancy of men in 9 out of the 13 countries. In several countries,
 12   II,     4.  2        |             related mortality (cause 13 in table 3) had a negative
 13   II,     4.  2        |              for men in 7 out of the 13 selected countries the decline
 14   II,     4.  2        |           women even in 9 out of the 13 countries. For Polish men
 15   II,     4.  2        |              for men in 8 out of the 13 selected countries and for
 16   II,     4.  2        |             negative in 7 out of the 13 countries. As women started
 17   II,     4.  2        |              expectancy in 12 of the 13 countries. In 9 of these
 18   II,     4.  3        |             Journal of Public Health 13(3): 6-14.~ ~Robine, J.-M.,
 19   II,     4.  3        |       Journal of Public Health 2003; 13:6-14.~ ~Robine, J.-M., C.
 20   II,     5.  2.  3    |              Table 5.2.4. WHO-MONICA 13 EU population. Mean annual
 21   II,     5.  2.  3    |          from 87 to 68 per 100.000), 13% in Baltic Europe countries (
 22   II,     5.  2.  7    |         Project. Eur J Public Health 13: 55-60~European society
 23   II,     5.  2.  7    |              Cardiovasc Prev Rehabil 13:562570.~Panico S, Palmieri
 24   II,     5.  3.  9    |           Strategies in Europe, 1213 July 2007, Strategies on
 25   II,     5.  3.  9    |           Strategies in Europe, 1213 July 2007, Strategies on
 26   II,     5.  3.  9    |      indicators. Eur J Public Health 13(3 Suppl):116-118.~ ~Parkin
 27   II,     5.  4.  2    |           LDL>2.6 mmol/l (>3 mmol/l)~13~Percent of diabetic subjects
 28   II,     5.  4.  2    |              BMI 25 kg/m2 , 30 kg/m2~13~Age at diagnosis of diabetes
 29   II,     5.  4.  2    |         creatinine in last 12 months~13~Percent of diabetic subjects
 30   II,     5.  4.  3    |        Results reported by OECD from 13 EU countries lead to a median
 31   II,     5.  4.  6    |            lifestyles. See Chapter 5.13. on overweight and obesity
 32   II,     5.  4.  6    |          control plans~In 2008, only 13 of the 27 EU Member States (
 33   II,     5.  4.  8    |            Clinical and Experimental 13(4), 245. 2001.~Boyle D,
 34   II,     5.  5.  1    |    prevalence of major depression is 13% in Western and Southern
 35   II,     5.  5.  1    |        projected lifetime prevalence 13-26% in the participating
 36   II,     5.  5.  1    |           people aged 50 and over in 13 EU Member States. They do
 37   II,     5.  5.  1    |             women (20%) than in men (13%) and increased with age.~ ~
 38   II,     5.  5.  2    |            This represents between 1.13 and 1.25 percent of the
 39   II,     5.  5.  2    |              the Hague Convention of 13 January 2000 on the International
 40   II,     5.  5.  2    |          article online, accessed on 13 December 2007)~ ~Cooper
 41   II,     5.  5.  3    |            adolescence in the age of 13 to 18; however, several
 42   II,     5.  5.  3    |         European adolescents between 13 and 16 years of age (3000
 43   II,     5.  5.  3    |            for 11-year-olds, 37% for 13-year-olds and 42% for 15-
 44   II,     5.  5.  3    |            in Europe by nutrition in 13-16 years adolescents across
 45   II,     5.  5.  3    |           ranks 1st and accounts for 13.7% of YLDs, followed by
 46   II,     5.  5.  3    |        optimal treatment compared to 13% with current intervention
 47   II,     5.  5.  3    |             N S W Public Health Bull 13(7):155-8.~Andlin-Sobocki
 48   II,     5.  5.  3    |            en.pdf; last accessed Dec 13, 2007.~European Commission (
 49   II,     5.  5.  3    |            en.htm; last accessed Dec 13, 2007.~European Commission (
 50   II,     5.  5.  3    |                    last accessed Dec 13, 2007.~World Health Organization (
 51   II,     5.  5.  3    |                    last accessed Dec 13, 2007.~World Health Organisation (
 52   II,     5.  5.  3    |                    last accessed Dec 13, 2007.~World Health Organization (
 53   II,     5.  5.  3    |                    last accessed Dec 13, 2007.~World Health Organization (
 54   II,     5.  5.  3    |                    last accessed Dec 13, 2007.~World Health Organization (
 55   II,     5.  5.  3    |          idiopathic 1.7; symptomatic 13.6), 6.7 per 100,000 for
 56   II,     5.  5.  3    |      revisited. Epileptic Disord 6:3-13.~Gaitatzis A, Carroll K,
 57   II,     5.  5.  3    |              Neurosurg Psychiatry 69:13-17.~Nashef L, Fish DR, Garner
 58   II,     5.  5.  3    |              to 80% (Spain), between 13% (Italy) and 48% (UK) for
 59   II,     5.  5.  3    |            MS for the year 2005 was €13 billion, i.e., €27 per European
 60   II,     5.  5.  3    |       centers. Cephalalgia Hungarica 13:68-70.~Battaglia M, Kesselring
 61   II,     5.  5.  3    |          Lodz. Cephalalgia Hungarica 13:63-64.~Boiko A, Deomina
 62   II,     5.  5.  3    |              Danes with MS. Int MS J 13:66-71.~Buehler JW. Surveillance (
 63   II,     5.  5.  3    |    University. Cephalalgia Hungarica 13:47-48.~Jedlicka P (1989):
 64   II,     5.  5.  3    |       protocols. Annals of Neurology 13:227231.~Poser S, Stickel
 65   II,     5.  5.  3    |              in Europe. Eur J Neurol 13: 700722.~Pugliatti M, Rosati
 66   II,     5.  5.  3    | multinational cost study. Mult Scler 13(8):1054-64. Erratum in:
 67   II,     5.  5.  3    |           Belgium. Neuroepidemiology 13:220-225.~Vukusic S, Van
 68   II,     5.  5.  3    |             from €2,500 (Estonia) – €13,000 (Switzerland) with an
 69   II,     5.  5.  3    |      Parkinson’s disease. Mov Disord 13(4):626-632.~Anderson C,
 70   II,     5.  5.  3    |   ascertainment of cases. Mov Disord 13(3):400-405.~Chrischilles
 71   II,     5.  5.  3    |      Parkinson’s disease. Mov Disord 13(3):406-413.~Clarke CE, Zobkiw
 72   II,     5.  5.  3    |              s disease. Eur J Neurol 13(11):1170-1185.~Hughes AJ,
 73   II,     5.  5.  3    |         Current opinion in neurology 13(4):427-430.~Tanner CM (2003):
 74   II,     5.  6.  3    |         incidence of RA range from 413 per 100,000 for adult males
 75   II,     5.  6.  3    |              000 for adult males and 13-36 per 100,000 for adult
 76   II,     5.  6.  3    |             France 0.32% and Italy 0.13%. In women, the prevalence
 77   II,     5.  6.  6    |           Survey. Ann Rheum Dis 52:6-13~Bergman S, Herrstrom P,
 78   II,     5.  7.  3    |             transplantation: 60% and 13%, respectively.~Mortality
 79   II,     5.  7.  7    |           Engl J Med 2004 Sep 23;351(13):1296-305.~Gorodetskaya
 80   II,     5.  7.  7    |  implications. J Am Soc Nephrol 2002;13(Suppl 1):S37-S40.~McKenna
 81   II,     5.  8.  3    |             centres of 16 countries (13 EU and EFTA countries) collected
 82   II,     5.  8.  3    |       Netherlands was 6.5. for mild, 13.3 for moderate, 3.7 for
 83   II,     5.  9.  2    |             atopic eczema in 6-7 and 13-15 years old were assessed
 84   II,     5.  9.  2    |            and 304 679 children aged 1314 years from 106 centres
 85   II,     5.  9.  2    |              them were among adults, 13 among children and two among
 86   II,     5.  9.  3    |             and 16.9% in children of 13.14 years of age), Romania (
 87   II,     5.  9.  3    |             older, while adolescents 13 to 14 years old presented
 88   II,     5.  9.  3    |              rhinitis varied between 13.5% and 23.6% (median 18.
 89   II,     5.  9.  3    |              9.3) identified that in 13 of the 20 studies reviewed,
 90   II,     5.  9.  3    |             of age-group than in the 1314 years of age-group: for
 91   II,     5.  9.  3    |        reported no changes); for the 1314 years of age-group, 11
 92   II,     5.  9.  4    |               6837 participants from 13 countries who previously
 93   II,     5.  9.  4    |             among 1450 children aged 13- to 14- and living in Brescia,
 94   II,     5.  9.  4    |            and clinical asthma among 13- to 14-yr-old adolescents
 95   II,     5. 10.  5    |               Council Directive 2000/13/EC (European Commission,
 96   II,     5. 10.  5    |            in Council Directive 2000/13/EC (European Commission,
 97   II,     5. 10.  7    |    Commission (2000): Directive 2000/13/EC of the European Parliament
 98   II,     5. 10.  7    |              amending Directive 2000/13/EC as regards indication
 99   II,     5. 10.  7    |         Annex IIIa of Directive 2000/13/EC of the European Parliament
100   II,     5. 10.  7    |         Annex IIIa to Directive 2000/13/EC of the European Parliament
101   II,     5. 10.  7    |              J Gastroenterol Hepatol 13: 741-747.~Strannegard O
102   II,     5. 11.  3    |         pierced skin has varied from 13 to 20% in the 1980s (B Larsson-Stymne
103   II,     5. 11.  3    |              students increased from 13 to 39% during the 19851995
104   II,     5. 11.  3    |              Contact Dermatitis,1985;13:289–293.~C Lidén, M Bruze,
105   II,     5. 11.  3    |            rates of SCC increased by 13.5% in men and 18.8% in women.
106   II,     5. 11.  7    |              Contact Dermatitis 1985;13:29-48.~ ~Levi F, Te VC,
107   II,     5. 12.  3    |           where rates were around 10-13/100,000 men in the early
108   II,     5. 12.  3    |            2002, Finland from 7.4 to 13.6, Ireland from 3.4 to 4.
109   II,     5. 12.  3    |            12.5 to 19.4, Poland from 13.0 to 15.9, and mainly Hungary,
110   II,     5. 13        |                                    5.13. Overweight, obesity and
111   II,     5. 14.  3    |          expenses. 245 169 dentists, 13 295 dental hygienists work
112   II,     5. 15.  1    |               in other words, around 13.5 million people in the
113   II,     5. 15.  6    |     Parliament and of the Council of 13 November 2007 on advanced
114   II,     6.  3.  4    |          200304 season in the other 13 countries. The highest consultation
115   II,     6.  3.  4    |  corresponding to an overall rate of 13 per 100 000 per year, with
116   II,     6.  3.  5    |                  In 2005, a total of 13 207 cases were reported
117   II,     6.  3.  6    |             of all cases. Lithuania (13.43 per 100 000 total population),
118   II,     6.  3.  6    |             countries, with Ireland (13.75 per 100 000) and the
119   II,     7.  3.  4    |        treated in hospital (Figure 7.13).~ ~Figure 7.13. Fatalities
120   II,     7.  3.  4    |             Figure 7.13).~ ~Figure 7.13. Fatalities and injured
121   II,     8.  1.  2    |              This survey covers only 13 Member States – the EU15
122   II,     8.  1.  5(3) |         Nations' General Assembly on 13 of December 2006.~
123   II,     8.  2.  1    |               SPID) in Finland was 0.13% based on the register of
124   II,     8.  2.  1    |             participating countries (13 MS and 1 EEA country).~The
125   II,     8.  2.  1    |     perspective. Eur J Public Health 13: 47-50; doi:10.1093/eurpub/
126   II,     8.  2.  1    |            47-50; doi:10.1093/eurpub/13.suppl_1.47~Walsh, P.N.,
127   II,     8.  2.  3    |       Audiology 1996;Supplement 42:9-13~ ~Uimonen S, Huttunen K,
128   II,     9            |              countries to a fifth of 13 year old boys in eight countries
129   II,     9.  1.  1    |            Reprod Biol 2002;103(1):4-13.~Apgar V (1953): A t. Curr.
130   II,     9.  2.  2    |              of adolescents aged 11, 13 and 15 years, who attend
131   II,     9.  2.  3    |          symptoms” for children aged 13-14 for those countries which
132   II,     9.  2.  3    |         rates of clinical asthma2 in 13- to 14-year-old children
133   II,     9.  2.  3(2) |          previous 12-month period in 13- to 14-year-old children)
134   II,     9.  2.  4    |              countries to a fifth of 13 year old boys in eight countries
135   II,     9.  2.  7    |        Eurobarometer Issue No. 246 p 13. 9 November, 2006~ ~European
136   II,     9.  2.  7    |            the field of health (2008-13), OJ No L 301, 20 November
137   II,     9.  3.  1    |         attempt Demographic Research 13(15), pp 363-388~ ~Haslam,
138   II,     9.  3.  2    |            Reprod Biol 2002;103(1):4-13.~ ~Ananth CV, Joseph KS,
139   II,     9.  3.  3    |           pregnancy in the age group 13-19 years (Imamura M et al,
140   II,     9.  3.  3    |        Encounter Module Project. May 13 2003. Available at: htt l (
141   II,     9.  4.  7    |             of Public Health, Volume 13, No. 2 p. 56-61. March 2005~ ~
142   II,     9.  5.  3    |                 to police~Hungaryd~· 13% in/have been in a rela en
143   II,     9.  5.  3    |             been drunk at the age of 13 or earlier. In Greece the
144   II,     9.  5.  6    |        Available at:~htt p~(Accessed 13.07.07)~ ~Austbury J (2002):
145   II,     9.  5.  6    |          Body and Society, 6(1), pp. 13-28.~ ~Risberg G, Hamber
146   II,     9.  5.  6    |             of Public Health, Volume 13, No. 2 p. 56-61. March 2005~ ~
147  III,    10.  1.  3    |         services. Recent Dev Alcohol 13:387-405.~Dahlgren, G. &
148  III,    10.  1.  3    |             Acta Psychiatr Scand 113:13-22.~Szklo M (2000): Confounding
149  III,    10.  1.  3    |             Germany. J Public Health 13(6):291-295.~Wiers RW, Sergeant
150  III,    10.  1.  3    |            Acta Paediatr Suppl 404:9-13.~Wood PD (1994): Physical activity,
151  III,    10.  2.  1    |            limit is at the ages from 13 - 20 years and the upper
152  III,    10.  2.  1    |         Nearly 18% of Europeans aged 13 to 15 are smokers, more
153  III,    10.  2.  1    |             in Ireland, but only 12%-13% of boys and 5%-7% of girls
154  III,    10.  2.  1    |              EU though, over 1 in 8 (13%) of 15-16 year old students
155  III,    10.  2.  1    |              by young men in Europe, 13,000 of whom die in the EU
156  III,    10.  2.  1    |          European Region, Stockoholm 13-15 April 2005 [conference
157  III,    10.  2.  1    |          ESPAD survey, between 1 and 13% (on average 4%) of school
158  III,    10.  2.  1    |              for the first time when 13 years old or younger. Among
159  III,    10.  2.  1    |            lifetime use of cannabis, 13% (3-20%) used it in the
160  III,    10.  2.  1    |           more than once a day among 13 year old schoolchildren
161  III,    10.  2.  1    |          among young people aged 11, 13 and 15 years HBSC studies
162  III,    10.  2.  1    |             active children aged 11, 13 and 15 years, selected countries
163  III,    10.  2.  1    |             are quoted in section5.13. Obesity, overweight and
164  III,    10.  2.  1    |             Society of Health, 116:7-13.~ ~Gordon-Larsen P et al. (
165  III,    10.  2.  1    |            weight and height in 11-, 13- and 15-year-old adolescents
166  III,    10.  2.  1    |           subjects (22,924 women and 13,031 men) who participated
167  III,    10.  2.  1    |       pre-obesity and obesity in the 13 and 15 year olds from the
168  III,    10.  2.  1    |         indicating that up to 34% of 13-year-old boys versus 24%
169  III,    10.  2.  1    |         overweight. Up to 9% of both 13-year-old and 15-year-old
170  III,    10.  2.  1    |            obese, as were 5% of both 13-year-old and 15-year-old
171  III,    10.  2.  1    |       Prevalence of overweight among 13-year-olds and 15-year-olds~ ~
172  III,    10.  2.  1    |       overweight in adolescents aged 13-14 more than doubled from
173  III,    10.  2.  1    |           labelling~ ~Directive 2000/13/EC on labelling, presentation
174  III,    10.  2.  1    |               2000b): Directive 2000/13/EC of the European Parliament
175  III,    10.  2.  4    |             locus on chromosome 1p36.13 and a type 2 diabetes locus
176  III,    10.  2.  4    |        metabolic syndrome. Obes Res, 13:2122-2131.~ ~Torhorst J,
177  III,    10.  3.  1    |             Directive 96/29/Euratom (13 May 1996). However, the
178  III,    10.  3.  1    |              of individual data from 13 European case-control studies.
179  III,    10.  3.  1    |          Burden of Disease Series No 13. Geneva, World Health Organization, (
180  III,    10.  4.  2    |             5% (the Netherlands) and~13% (import) involving~incidents
181  III,    10.  4.  2    |            2000): Directive No. 2000/13/EC of the European Parliament
182  III,    10.  4.  2    |              methods and approaches13-14 July 2006. 155.~ ~EFSA (
183  III,    10.  4.  2    |    micro-organisms in food and feed. 13-14 December 2004. pp. 142.
184  III,    10.  4.  3    |           that in these regions over 13 000 children aged under
185  III,    10.  4.  3    |       populated country like Sweden, 13% of the population permanently
186  III,    10.  4.  4    |             see Annex 1 of Chapter 5.13.~ ~The increasing production,
187  III,    10.  4.  5    |            will be introduced over a 13 year period, starting in
188  III,    10.  5.  1    |             information. Indoor Air, 13:53-64.~ DEFRA (2004): Review
189  III,    10.  5.  2    |             Journal of Rural Health. 13(3), 253-256.~ ~Jones A,
190  III,    10.  5.  3    |              and social conditions13/2006~ ~Current working conditions~
191  III,    10.  5.  3    |           more frequent among women. 13% of all workers feared that
192  III,    10.  5.  3    |           risk factors (table 10.5.3.13). Exposures to vibrations
193  III,    10.  5.  3    |         working time.~ ~Table 10.5.3.13. Physical risks factors
194  III,    10.  6.  1    |        four-year intervals among 11, 13 and 15 year old school children.
195  III,    10.  6.  1    |            11 year old girls, 65% of 13 year old girls and 61% of
196  III,    10.  6.  1    |              the Netherlands, 92% of 13 year old girls, and in Slovenia,
197  III,    10.  6.  1    |             11 year old boys, 74% of 13 year old boys, and 69% of
198  III,    10.  6.  1    |              44% of boys, 78% of the 13 year old girls and 56% of
199  III,    10.  6.  1    |             old Hungarian girls only 13% had used electronic contacts,
200  III,    10.  6.  1    |           electronic contacts, among 13 year old Hungarian girls
201   IV,    11.  5.  3    |         European countries~Figure 11.13. Exchanges and import/export
202   IV,    11.  5.  3    |         place. For the living donor, 13 countries have binding criteria,
203   IV,    11.  6.  2    |           are summarized in Table 11.13. Also in some countries,
204   IV,    11.  6.  2    |          Mossialos 2008).~ ~Table 11.13. Examples for cost sharing
205   IV,    11.  6.  5    |             in England." Euro Health 13(1): 13-16.~ ~Brook R, McGlynn
206   IV,    11.  6.  5    |         England." Euro Health 13(1): 13-16.~ ~Brook R, McGlynn E
207   IV,    11.  6.  5    |              Journal of Medicine 335(13): 966-970.~ ~Brook RH, McGlynn
208   IV,    11.  6.  5    |          Journal Quality Health Care 13(6): 439-46.~ ~Evans RG,
209   IV,    11.  6.  5    |         Project 3: Working Paper No. 13.~ ~McCarthy D, Blumenthal
210   IV,    11.  6.  5    |            Protection Systems in the 13 Applicant Countries: Latvia
211   IV,    11.  6.  5    |            Europe." Health Economics 13(7): 629-647.~ ~van Doorslaer
212   IV,    12.  1        |          Treaty, formally adopted on 13 December 2007 in Lisbon,
213   IV,    12.  4        |      Framework Programme (CIP) (2007-13)~ENV~LIFE - supporting environmental
214   IV,    12. 10        |            high~Insurance public law 13 august 2004 : institution
215   IV,    12. 10        |        10March~Despacho nb 242/96 of 13 August~ -PERH – implementation
216   IV,    13            |                                      13.~THE WAY FORWARD~ ~
217   IV,    13.  1        |                                      13.1. Differences in selected
218   IV,    13.  1        |             mortality data see Table 13.3). Large differences have
219   IV,    13.  1        |      different EU countries.~ ~Table 13.1. Standardised Death Rates
220   IV,    13.  2        |                                      13.2. Assessing priorities
221   IV,    13.  2.  1    |                                      13.2.1. Disability adjusted
222   IV,    13.  2.  2    |                                      13.2.2. Burden of diseases~ ~
223   IV,    13.  2.  2    |              disease in the OECD and 13% in non-OECD countries.~ ~
224   IV,    13.  2.  2    |         dominate the picture (Figure 13.1).~ ~Figure 13.1. Patterns
225   IV,    13.  2.  2    |               Figure 13.1).~ ~Figure 13.1. Patterns of total and
226   IV,    13.  2.  2    |        population, EU25, EU15 (Table 13.4).~ ~Table 13.2. Global
227   IV,    13.  2.  2    |           EU15 (Table 13.4).~ ~Table 13.2. Global burden of disease
228   IV,    13.  2.  2    |          diseases are shown in Table 13.5.~ ~ ~Table 13.3. Additional
229   IV,    13.  2.  2    |             in Table 13.5.~ ~ ~Table 13.3. Additional estimations
230   IV,    13.  2.  2    |           ranks 1st and accounts for 13.7% of YLDs, followed by
231   IV,    13.  2.  3    |                                      13.2.3. Burden of diseases
232   IV,    13.  2.  3    |           were estimated as follows: 13.2% of total disease burden
233   IV,    13.  2.  3    |             range from 2-6%.~ ~Table 13.4. Burden of disease in
234   IV,    13.  2.  3    |          three determinants in Table 13.6 are typically associated
235   IV,    13.  2.  3    |           selected conditions. Table 13.7 presents a comparison
236   IV,    13.  2.  3    |       diseases and depression. Table 13.7 also shows that the demonstrable
237   IV,    13.  2.  3    |          different people.~ ~ ~Table 13.5. Annual health loss (in
238   IV,    13.  2.  4    |                                      13.2.4. Avoidable Burden of
239   IV,    13.  2.  4    |            European countries (Table 13.8).~ ~ ~Table 13.6. WHO
240   IV,    13.  2.  4    |               Table 13.8).~ ~ ~Table 13.6. WHO estimates for preventable
241   IV,    13.  2.  4    |            the European Union (Table 13.6) are smoking, having a
242   IV,    13.  2.  4    |           the data reported in Table 13.6 that these risk factors
243   IV,    13.  3        |                                      13.3. Demographic and socio-economic
244   IV,    13.  4        |                                      13.4. Migration policies~ ~
245   IV,    13.  5        |                                      13.5. Demands on healthcare
246   IV,    13.  6        |                                      13.6. Prioritising children’
247   IV,    13.  6.  1    |                                      13.6.1 Measurement of burden
248   IV,    13.  6.  2    |                                      13.6.2 Health Services for
249   IV,    13.  6.  2    |                                      13.6.2.1 Hospitals~ ~Children
250   IV,    13.  6.  2    |                                      13.6.2.2 Human Resources for
251   IV,    13.  6.  2    |                                      13.6.2.3 Primary Health Care
252   IV,    13.  6.  2    |                                      13.6.2.4 School Health and
253   IV,    13.  6.  2    |                                      13.6.2.5 Child Health Service
254   IV,    13.  6.  2    |                                      13.6.2.6 Pharmaceuticals for
255   IV,    13.  6.  3    |                                      13.6.3 Health Systems and Access
256   IV,    13.  7        |                                      13.7. Innovation~ ~Never before
257   IV,    13.  7.  1    |                                      13.7.1. “Innovation Cluster”
258   IV,    13.  7.  2    |                                      13.7.2. “Lead Marketinitiative~ ~
259   IV,    13.  7.  2    |           graduates, who now make up 13 per thousand 20-29 year
260   IV,    13.  7.  3    |                                      13.7.3. Research~ ~One of the
261   IV,    13.  7.  4    |                                      13.7.4. Ethical issues~ ~Ethical
262   IV,    13.  7.  5    |                                      13.7.5. Personal data protection
263   IV,    13.  8        |                                      13.8. Civil society involvement
264   IV,    13.  9        |                                      13.9. References~ ~Andlin-Sobocki
265   IV,    13.  9        |            Journal of Public Health, 13, 3, Supplement, 38-46.~ ~